NEW YORK, January 19, 2017 /PRNewswire/ --
Operators in the Medical Laboratories and Research industry provide analytic services to identify or determine the nature and cause of a disease or injury, through the evaluation of a patient's history, examination, and data. These services are provided to health care providers or patients upon referral from health practitioners. This morning, Stock-Callers.com tracks the performances of PAREXEL International Corp. (NASDAQ: PRXL), Charles River Laboratories International Inc. (NYSE: CRL), PRA Health Sciences Inc. (NASDAQ: PRAH), and Invitae Corp. (NYSE: NVTA). Learn more about these stocks by downloading their free report at:
Waltham, Massachusetts headquartered PAREXEL International Corp.'s stock finished Wednesday's session 0.62% lower at $71.00 with a total trading volume of 712,980 shares. The Company's shares have advanced 8.43% in the past month, 7.04% over the previous three months, and 8.03% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 13.27% and 10.41%, respectively. Furthermore, shares of PAREXEL International, which provides clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide, have a Relative Strength Index (RSI) of 80.01.
As per a SEC filing dated January 09th, 2017, the Chairman and CEO and the Corporate Vice President and Interim CFO of PAREXEL International approved a plan to restructure the Company's operations on January 6th, 2017, to improve its productivity and efficiency, simplify the organization, and streamline decision-making. The Company expects to record a pre-tax charge in Q3 FY17 in the range of $20 million to $27 million, with the remainder of the charges to be incurred by the end of FY18. These actions are expected to result in pre-tax charges in the range of $25 million to $35 million, all of which are anticipated to be cash expenditures. The Company anticipates completing restructuring activities by the end of FY18, and expects the charges to result in annual pre-tax savings of approximately $7 million to $10 million over the course of FY17 and approximately $30 million to $40 million on an annualized basis when fully completed. The free research report on PRXL is available at:
Charles River Laboratories
Shares in Wilmington, Massachusetts headquartered Charles River Laboratories International Inc. ended at $80.02, up 0.29% from the last trading session. The stock recorded a trading volume of 425,672 shares. The Company's shares have gained 4.60% in the last one month and 5.03% since the start of this year. The stock is trading 6.93% above its 50-day moving average. Moreover, shares of Charles River Laboratories International, which provides drug discovery and preclinical development services worldwide, have an RSI of 63.24.
On December 01st, 2016, Charles River Laboratories launched a full, end-to-end service offering of CRISPR/Cas9 genome engineering technology. Through a licensing arrangement with the Broad Institute of MIT and Harvard, Charles River can now offer custom in vivo and in vitro genome editing. With this technology, Charles River will be able to develop more translational research models that will ultimately improve the efficiency and effectiveness of the drug discovery process. The complimentary report on CRL can be downloaded at:
PRA Health Sciences
Raleigh, North Carolina headquartered PRA Health Sciences Inc.'s stock ended yesterday's session 0.89% lower at $55.74 with a total trading volume of 420,856 shares. The Company's shares have advanced 0.36% in the past month, 3.45% over the previous three months, and 1.12% on an YTD basis. The stock is trading 1.22% above its 50-day moving average and 10.74% above its 200-day moving average. Additionally, shares of PRA Health Sciences, which provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide, have an RSI of 49.56. Visit us today and download our complete research report on PRAH for free at:
At the close on Wednesday, shares in San Francisco, California headquartered Invitae Corp. recorded a trading volume of 190,578 shares. The stock finished 1.88% lower at $8.34. The Company's shares have gained 15.99% in the last one month, 11.35% in the previous three months, and 5.04% on an YTD basis. The stock is trading above its 50-day moving average by 9.17%. Furthermore, shares of Invitae, which focuses on bringing comprehensive genetic information into mainstream medical practice to enhance the quality of healthcare, have an RSI of 53.30.
On January 09th, 2017, Invitae announced that Sean George, Ph.D., its Co-Founder and current President and Chief Operating Officer, has been named Chief Executive Officer for the Company. Current Chairman and Chief Executive Officer, Randy Scott, will become Executive Chairman of the Board of Directors and remain full time at the Company. The appointments were effective immediately. Get free access to your technical report on NVTA at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA